J&J inks a $1.15B dis­cov­ery deal with Pep­tiDream; Medi­vir plots PhI­II HDAC pro­gram

→ Tokyo-based Pep­tiDream has struck a dis­cov­ery deal with J&J worth up to $1.15 bil­lion. In the deal Pep­tiDream will use its plat­form tech to “iden­ti­fy macro­cyclic/con­strained pep­tides against mul­ti­ple meta­bol­ic and car­dio­vas­cu­lar tar­gets of in­ter­est se­lect­ed by Janssen, and to op­ti­mize hit pep­tides in­to ther­a­peu­tic pep­tides or small mol­e­cule prod­ucts.”

→ Swe­den’s Medi­vir says that they’ve gath­ered some pos­i­tive re­sults from a Phase II study of their HDAC in­hibitor remetino­s­tat for cu­ta­neous T-cell lym­phoma. Ear­ly stage pa­tients in the 1% remetino­s­tat gel BID arm had the high­est pro­por­tion of con­firmed re­spons­es (8/20, 40%), in­clud­ing one com­plete re­sponse. The biotech says it is now plan­ning a piv­otal Phase III pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER